Interne Geneeskunde

De vakgroep beoefend de Interne Geneeskunde in al haar diagnostische en klinische mogelijkheden.

De vakgroep bestaat uit de volgende sub-specialismen: Oncologie, Hematologie, Nefrologie, Vasculaire geneeskunde, Algemeen Interne, Endocrinologen en Intensive Care.
Er lopen diverse onderzoekslijnen met origineel wetenschappelijk onderzoek. De vakgroep Interne Geneeskunde verzorgt het perifere deel van de opleiding tot internist (4 jaar) met daarin onder andere de stages oncologie, hematologie en nefrologie. Iedere interne sectie levert top klinische zorg waarbij de patiënt centraal staat. De sfeer in de maatschap is zonder meer open en stimulerend.

 

Leden

dr. E.F.H. (Eric) van Bommel

dr. E.F.H. (Eric) van Bommel

Nefrologie, vasculaire geneeskunde

BIG: 19020116401

J. (Joan) van den Bosch

J. (Joan) van den Bosch

Oncologie

BIG: 89038103301

dr. S.C.C. (Simone) Hartong

dr. S.C.C. (Simone) Hartong

Vasculaire geneeskunde

BIG: 49043157701

dr. R.M. (Rosalie) Kiewiet-Kemper

dr. R.M. (Rosalie) Kiewiet-Kemper

Endocrinologie, obesitas

BIG: 29049211001

J.J.E.M. (Jos) Kitzen

J.J.E.M. (Jos) Kitzen

Oncologie

BIG: 39048440501

dr. M.D. (Mark-David) Levin

dr. M.D. (Mark-David) Levin

Hematologie

BIG: 09046525401

J.A.A. (Ton) Meijer

J.A.A. (Ton) Meijer

Endocrinologie

BIG: 09046061301

dr. M.W.C.J. (Mariëtte) Schoofs

dr. M.W.C.J. (Mariëtte) Schoofs

Endocrinologie

BIG: 19051657201

dr. P.J.H. (Peter) Smak Gregoor

dr. P.J.H. (Peter) Smak Gregoor

Nefrologie, vasculaire geneeskunde

BIG: 89032851501

M. (Marija) Trajkovic

M. (Marija) Trajkovic

Oncologie

BIG: 39064201201

E.J.H.M. (Ernst-Jan) van der Weijgert

E.J.H.M. (Ernst-Jan) van der Weijgert

Algemene interne geneeskunde

BIG: 69024888401

dr. P.E. (Peter) Westerweel

dr. P.E. (Peter) Westerweel

Hematologie, duikgeneeskunde

BIG: 89061093201

dr. E.T. (Elske ) Massolt

dr. E.T. (Elske ) Massolt

Endocrinologie

BIG: 59064796101

E. (Eva ) de Jongh

E. (Eva ) de Jongh

Hematologie

BIG: 19909624101

dr. J.B. (Jeroen) van der Net

dr. J.B. (Jeroen) van der Net

Nefrologie

BIG: 39064434101

dr. E.W. (Esther) Bouman

dr. E.W. (Esther) Bouman

Oncologie

BIG: 49913614401

M. (Marieke) van der Zwan

M. (Marieke) van der Zwan

Internist-nefroloog

BIG: 19912164901

Dordwijk

Publicaties

01mei

Platelet Transfusion before CVC Placement in Patients with Thrombocytopenia.

»
01mei

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

»
01mei

High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.

»
01mei

A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.

»
01apr

Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome.

»
01apr

Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects.

»
01apr

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation.

»
01mrt

High-risk additional cytogenetic aberrations in a Dutch chronic phase chronic myeloid leukemia patient population.

»
01mrt

Risk of cancer after ST-segment-elevation myocardial infarction.

»
01feb

Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study.

»
01jan

Treatment patterns and clinical outcomes of asciminib in a real-world multi-resistant chronic myeloid leukemia patient population.

»
01jan

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019.

»
01dec

Starting home telemonitoring and oxygen therapy directly after emergency department assessment appears to be safe in COVID-19 patients.

»
01nov

Overall survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR) : a randomized, Open-Label, Phase III Trial.

»
01nov

Adherence to quality indicators in chronic myeloid leukemia care : results from a population-based study in The Netherlands.

»
01okt

Prognostic value of positron emission tomography/computed tomography in transplanteligible newly diagnosed multiple myeloma patients from CASSIOPEIA : the CASSIOPET study.

»
01aug

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

»
01aug

Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients.

»
01aug

Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.

»
01aug

Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism.

»
01aug

Hair Repigmentation Induced by Nilotinib

»
01aug

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

»
01jul

Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with Cancer.

»
01jul

DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.

»
01jul

Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome

»
01jun

Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

»
01jun

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

»
01mei

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21 R110.

»
01apr

Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018.

»
01apr

The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.

»
01mrt

Clinical significance of soluble interleukin-2 receptor measurement in patients with idiopathic retroperitoneal fibrosis.

»
01mrt

Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.

»
01mrt

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands.

»
01mrt

A Patient with Moderate Intellectual Disability and 49, XXXYY Karyotype.

»
01mrt

Establishing a Multicenter Network for Patients With Thyroid Nodules and Cancer: Effects on Referral Patterns.

»
01feb

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry.

»
01feb

Radiofrequency ablation for benign symptomatic thyroid nodules in the Netherlands: successful introduction of a minimally-invasive treatment option improving quality of life.

»
01jan

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.

»
01jan

Introducing the importance and difficulties of a three-step approach to improve nonadherence to antihypertensive drugs: a case series.

»
01dec

Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features.

»
01dec

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population-based study in the Netherlands, 1989-2018.

»
01nov

Abdominal aortic diameter and cardiovascular status in patients with idiopathic retroperitoneal fibrosis.

»
01nov

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study.

»
01nov

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.

»
01nov

Change in Thyroid Hormone Metabolite concentrations across Different Thyroid States.

»
01nov

2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.

»
01okt

Efficacy and Safety of Daratumumab Combined With All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma

»
01sep

Light Therapy for Cancer-Related Fatigue in (Non-)Hodgkin Lymphoma Survivors: Results of a Randomized Controlled Trial.

»
01sep

Ruling out Pulmonary Embolism in Patients with (Suspected) COVID-19-A Prospective Cohort Study.

»
01sep

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

»
01aug

The accuracy of mean corpuscular volume guided anaemia classification in primary care.

»
01aug

Unmet supportive care needs, anxiety and depression in haematology patients during watch-and-wait.

»
01aug

High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry

»
01jul

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.

»
01mei

Paroxysmal localized Hyperhidrosis, a case-report: When excessive sweating occurs in combination with severe headaches.

»
01mei

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

»
01mei

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.

»
01feb

Paroxysmal localized Hyperhidrosis, a case-report: When excessive sweating occurs in combination with severe headaches.

»
01feb

Adalimumab-induced platelet antibodies resulting in severe thrombocytopenia.

»
01feb

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.

»
01feb

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.

»
01feb

Improving the identification of frail elderly newly diagnosed multiple myeloma patients.

»
01feb

Conditional relative survival among adult patients with chronic myeloid leukemia in the tyrosine kinase inhibitor era: a population-based study in the Netherlands.

»
01jan

COVID-19 vaccination in patients with immune thrombocytopenia.

»
01jan

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?

»
01jan

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients.

»
01jan

Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.

»
01jan

A bispecific single domain antibody boosts autologous Vγ9Vδ2-T cell responses towards CD1d in chronic lymphocytic leukemia.

»
01dec

Retroperitoneal fibrosis and betablocking agents: is there an association?

»
01dec

Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial.

»
01dec

Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

»
01dec

Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study.

»
01nov

Diffuse alveolar hemorrhage as an early complication of alemtuzumab treatment: A case report of a multiple sclerosis patient and an overview of 14 cases

»
01nov

A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study.

»
01nov

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice.

»
01nov

A bispecific antibody antagonizes pro-survival CD40 signaling and promotes Vγ9Vδ2 T cell-mediated antitumor responses in human B-cell malignancies.

»
01nov

Tyrosine kinase inhibitor treatment discontinuation in chronic myeloid leukemia: patient views.

»
01nov

Multidisciplinary treatment of metstatic prostate cancer.

»
01okt

Human CXCR5+ PD-1+ CD8 T cells in healthy individuals and patients with hematologic malignancies

»
01okt

Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

»
01okt

Debilitating Venous Claudication Secondary to Retroperitoneal Fibrosis.

»
01okt

Signalering, monitoring en behandeling van (risico op) ondervoeding bij intensieve behandeling voor hematologische maligniteiten.

»
01okt

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations.

»
01okt

Reading the B cell receptor Immunome in Chronic Lymphocytic Leukemia: Revelations and Applications

»
01sep

Spontaneous remission of unidentified Cushing’s disease revealed by hair cortisol analysis

»
01sep

Reading the B cell receptor Immunome in Chronic Lymphocytic Leukemia: Revelations and Applications.

»
01sep

HOVON 159: een prospectieve, multicenter, fase 2-studie naar behandeling van chronische lymfatische leukemie met venetoclax en acalabrutinib bij terugkeer van de ziekte na eerdere behandeling met venetoclax in combinatie met immuuntherapie.

»
01sep

Obesity-induced AA amyloidosis: A diagnosis of exclusion.

»
01sep

The Influence of (Co-)Medication on Haemostatic Biomarkers. / De invloed van (co-)medicatie op biomarkers van de stolling.

»
01aug

A new diagnostic work-up for defining anemia etiologies: a cohort study in patients ≥ 50 years in general practices.

   

»
01aug

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy; results from the HOVON 109 study.

»
01aug

Survival and Quality of Life after Early Discharge in Low-Risk Pulmonary Embolism.

»
01aug

Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation.

»
01aug

Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.

»
01aug

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.

   

»
01aug

Postoperative parathyroid hormone levels as a predictor for persistent hypoparathyroidism.

»
01jul

Preventing overuse of laboratory diagnostics: a case study into diagnosing anaemia in Dutch general practice.

»
01jul

Intimal angiosarcoma masquerading as retroperitoneal fibrosis.

   

»
01jul

Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study.

»
01jul

Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study.

»
01jul

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

     

»
01jul

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

»
01jul

Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma

»
01jul

European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations.

»
01jun

Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome.

»
01jun

Primary therapy and relative survival among elderly patients with chronic myeloid leukemia: a population-based study in the Netherlands, 1989-2017.

»
01jun

Response and Adherence to Nilotinib in Daily Practice (RAND Study): An In-Depth Observational Study of Chronic Myeloid Leukemia Patients Treated With Nilotinib.

»
01mei

Survival Continues to Increase in Chronic Lymphocytic Leukaemia: A Population-Based Analysis Among 20 468 Patients Diagnosed in the Netherlands Between 1989 and 2016.

»
01mei

Long term follow up of mTOR inhibition for Erdheim-Chester disease.

»
01mei

The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach.

»
01mei

Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice.

»
01apr

Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice.

»
01apr

Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.

»
01apr

Results of the prematurely terminated TEMPLE randomized controlled trial in patients with myelodysplastic syndrome: liberal versus restrictive red blood cell transfusion threshold.

»
01apr

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

»
01apr

Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate.

   

»
01mrt

Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma.

»
01mrt

A rare case of Waldenström’s macroglobulinaemia-associated cryoglobulinaemia vasculitis.

»
01mrt

Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.

   

»
01mrt

An Exceptional Vulvar Tumor: Myeloid Sarcoma of the Labia Majora.

»
01mrt

Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.

»
01mrt

Diving with hypertension and antihypertensive drugs.

»
02feb

Richtlijn voor diagnostiek en behandeling van chronische lymfatische leukemie/ kleincellig lymfocytair lymfoom.

»
01feb

The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands.

»
01feb

Validation of the FIRST Simplified Frailty Scale Using the ECOG Performance Status Instead of Patient-Reported Activities.

»
01feb

Functional Differences Between EBV- and CMVSpecific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL.

»
01feb

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

»
01feb

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial.

»
01jan

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.

»
Toon meer publicaties

Beeldmateriaal

of login met gebruikersnaam